6月23日，Moderna盘中上涨5.45%，报62.745美元/股，成交额1.57亿美元。
消息面上，该股前一交易日因短期获利回吐压力大跌逾5%，但基本面利好仍在。此前公司mRNA流感疫苗mFlusiva获FDA顾问委员会9-0全票推荐批准，数据显示该疫苗在50岁以上人群中可引发强烈免疫反应，若获批将成为美国首款mRNA季节性流感疫苗。FDA最终审批决定预计8月初做出。同时，公司已完成组织架构调整，任命Ester Banque为首席商务官，为未来两年内多达三款新疫苗上市做准备，核心催化逻辑未变，前日急跌后买盘回补推动股价反弹。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.